Pharmacogenetics for genes associated with age-related macular degeneration in the comparison of AMD treatments trials (CATT)

Stephanie A. Hagstrom, Gui Shuang Ying, Gayle J T Pauer, Gwen M. Sturgill-Short, Jiayan Huang, David G. Callanan, Ivana K. Kim, Michael Klein, Maureen G. Maguire, Daniel F. Martin

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Purpose: To evaluate the pharmacogenetic relationship between genotypes of single nucleotide polymorphisms (SNPs) known to be associated with age-related macular degeneration (AMD) and response to treatment with ranibizumab (Lucentis; Genentech, South San Francisco, CA) or bevacizumab (Avastin; Genentech) for neovascular AMD. Design: Clinical trial. Participants: Eight hundred thirty-four (73%) of 1149 patients participating in the Comparison of AMD Treatments Trials (CATT) were recruited through 43 CATT clinical centers. Methods: Each patient was genotyped for SNPs rs1061170 (CFH), rs10490924 (ARMS2), rs11200638 (HTRA1), and rs2230199 (C3), using TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA). Main Outcomes Measures: Genotypic frequencies were compared with clinical measures of response to therapy at one year, including mean visual acuity (VA), mean change in VA, 15-letter or more increase in VA, retinal thickness, mean change in total foveal thickness, presence of fluid on OCT, presence of leakage on fluorescein angiography (FA), mean change in lesion size, and mean number of injections administered. Differences in response by genotype were evaluated with tests of linear trend calculated from logistic regression models for categorical outcomes and linear regression models for continuous outcomes. To adjust for multiple comparisons, P≤0.01 was considered statistically significant. Results: No statistically significant differences in response by genotype were identified for any of the clinical measures studied. Specifically, there were no high-risk alleles that predicted final VA or change in VA, the degree of anatomic response (fluid on OCT or FA, retinal thickness, change in total foveal thickness, change in lesion size), or the number of injections. Furthermore, a stepwise analysis failed to show a significant epistatic interaction among the variants analyzed; that is, response did not vary by the number of risk alleles present. The lack of association was similar whether patients were treated with ranibizumab or bevacizumab or whether they received monthly or pro re nata dosing. Conclusions: Although specific alleles for CFH, ARMS2, HTRA1, and C3 may predict the development of AMD, they did not predict response to anti-vascular endothelial growth factor therapy. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

Original languageEnglish (US)
Pages (from-to)593-599
Number of pages7
JournalOphthalmology
Volume120
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Pharmacogenetics
Macular Degeneration
Visual Acuity
Single Nucleotide Polymorphism
Fluorescein Angiography
Genes
Alleles
Genotype
Linear Models
Logistic Models
Clinical Trials
Therapeutics
Injections
San Francisco
Disclosure
Vascular Endothelial Growth Factor A
Outcome Assessment (Health Care)
Ranibizumab
Bevacizumab

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Hagstrom, S. A., Ying, G. S., Pauer, G. J. T., Sturgill-Short, G. M., Huang, J., Callanan, D. G., ... Martin, D. F. (2013). Pharmacogenetics for genes associated with age-related macular degeneration in the comparison of AMD treatments trials (CATT). Ophthalmology, 120(3), 593-599. https://doi.org/10.1016/j.ophtha.2012.11.037

Pharmacogenetics for genes associated with age-related macular degeneration in the comparison of AMD treatments trials (CATT). / Hagstrom, Stephanie A.; Ying, Gui Shuang; Pauer, Gayle J T; Sturgill-Short, Gwen M.; Huang, Jiayan; Callanan, David G.; Kim, Ivana K.; Klein, Michael; Maguire, Maureen G.; Martin, Daniel F.

In: Ophthalmology, Vol. 120, No. 3, 03.2013, p. 593-599.

Research output: Contribution to journalArticle

Hagstrom, SA, Ying, GS, Pauer, GJT, Sturgill-Short, GM, Huang, J, Callanan, DG, Kim, IK, Klein, M, Maguire, MG & Martin, DF 2013, 'Pharmacogenetics for genes associated with age-related macular degeneration in the comparison of AMD treatments trials (CATT)', Ophthalmology, vol. 120, no. 3, pp. 593-599. https://doi.org/10.1016/j.ophtha.2012.11.037
Hagstrom, Stephanie A. ; Ying, Gui Shuang ; Pauer, Gayle J T ; Sturgill-Short, Gwen M. ; Huang, Jiayan ; Callanan, David G. ; Kim, Ivana K. ; Klein, Michael ; Maguire, Maureen G. ; Martin, Daniel F. / Pharmacogenetics for genes associated with age-related macular degeneration in the comparison of AMD treatments trials (CATT). In: Ophthalmology. 2013 ; Vol. 120, No. 3. pp. 593-599.
@article{2f983f7ed29b46d9b022e4a1e5738c42,
title = "Pharmacogenetics for genes associated with age-related macular degeneration in the comparison of AMD treatments trials (CATT)",
abstract = "Purpose: To evaluate the pharmacogenetic relationship between genotypes of single nucleotide polymorphisms (SNPs) known to be associated with age-related macular degeneration (AMD) and response to treatment with ranibizumab (Lucentis; Genentech, South San Francisco, CA) or bevacizumab (Avastin; Genentech) for neovascular AMD. Design: Clinical trial. Participants: Eight hundred thirty-four (73{\%}) of 1149 patients participating in the Comparison of AMD Treatments Trials (CATT) were recruited through 43 CATT clinical centers. Methods: Each patient was genotyped for SNPs rs1061170 (CFH), rs10490924 (ARMS2), rs11200638 (HTRA1), and rs2230199 (C3), using TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA). Main Outcomes Measures: Genotypic frequencies were compared with clinical measures of response to therapy at one year, including mean visual acuity (VA), mean change in VA, 15-letter or more increase in VA, retinal thickness, mean change in total foveal thickness, presence of fluid on OCT, presence of leakage on fluorescein angiography (FA), mean change in lesion size, and mean number of injections administered. Differences in response by genotype were evaluated with tests of linear trend calculated from logistic regression models for categorical outcomes and linear regression models for continuous outcomes. To adjust for multiple comparisons, P≤0.01 was considered statistically significant. Results: No statistically significant differences in response by genotype were identified for any of the clinical measures studied. Specifically, there were no high-risk alleles that predicted final VA or change in VA, the degree of anatomic response (fluid on OCT or FA, retinal thickness, change in total foveal thickness, change in lesion size), or the number of injections. Furthermore, a stepwise analysis failed to show a significant epistatic interaction among the variants analyzed; that is, response did not vary by the number of risk alleles present. The lack of association was similar whether patients were treated with ranibizumab or bevacizumab or whether they received monthly or pro re nata dosing. Conclusions: Although specific alleles for CFH, ARMS2, HTRA1, and C3 may predict the development of AMD, they did not predict response to anti-vascular endothelial growth factor therapy. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.",
author = "Hagstrom, {Stephanie A.} and Ying, {Gui Shuang} and Pauer, {Gayle J T} and Sturgill-Short, {Gwen M.} and Jiayan Huang and Callanan, {David G.} and Kim, {Ivana K.} and Michael Klein and Maguire, {Maureen G.} and Martin, {Daniel F.}",
year = "2013",
month = "3",
doi = "10.1016/j.ophtha.2012.11.037",
language = "English (US)",
volume = "120",
pages = "593--599",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Pharmacogenetics for genes associated with age-related macular degeneration in the comparison of AMD treatments trials (CATT)

AU - Hagstrom, Stephanie A.

AU - Ying, Gui Shuang

AU - Pauer, Gayle J T

AU - Sturgill-Short, Gwen M.

AU - Huang, Jiayan

AU - Callanan, David G.

AU - Kim, Ivana K.

AU - Klein, Michael

AU - Maguire, Maureen G.

AU - Martin, Daniel F.

PY - 2013/3

Y1 - 2013/3

N2 - Purpose: To evaluate the pharmacogenetic relationship between genotypes of single nucleotide polymorphisms (SNPs) known to be associated with age-related macular degeneration (AMD) and response to treatment with ranibizumab (Lucentis; Genentech, South San Francisco, CA) or bevacizumab (Avastin; Genentech) for neovascular AMD. Design: Clinical trial. Participants: Eight hundred thirty-four (73%) of 1149 patients participating in the Comparison of AMD Treatments Trials (CATT) were recruited through 43 CATT clinical centers. Methods: Each patient was genotyped for SNPs rs1061170 (CFH), rs10490924 (ARMS2), rs11200638 (HTRA1), and rs2230199 (C3), using TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA). Main Outcomes Measures: Genotypic frequencies were compared with clinical measures of response to therapy at one year, including mean visual acuity (VA), mean change in VA, 15-letter or more increase in VA, retinal thickness, mean change in total foveal thickness, presence of fluid on OCT, presence of leakage on fluorescein angiography (FA), mean change in lesion size, and mean number of injections administered. Differences in response by genotype were evaluated with tests of linear trend calculated from logistic regression models for categorical outcomes and linear regression models for continuous outcomes. To adjust for multiple comparisons, P≤0.01 was considered statistically significant. Results: No statistically significant differences in response by genotype were identified for any of the clinical measures studied. Specifically, there were no high-risk alleles that predicted final VA or change in VA, the degree of anatomic response (fluid on OCT or FA, retinal thickness, change in total foveal thickness, change in lesion size), or the number of injections. Furthermore, a stepwise analysis failed to show a significant epistatic interaction among the variants analyzed; that is, response did not vary by the number of risk alleles present. The lack of association was similar whether patients were treated with ranibizumab or bevacizumab or whether they received monthly or pro re nata dosing. Conclusions: Although specific alleles for CFH, ARMS2, HTRA1, and C3 may predict the development of AMD, they did not predict response to anti-vascular endothelial growth factor therapy. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

AB - Purpose: To evaluate the pharmacogenetic relationship between genotypes of single nucleotide polymorphisms (SNPs) known to be associated with age-related macular degeneration (AMD) and response to treatment with ranibizumab (Lucentis; Genentech, South San Francisco, CA) or bevacizumab (Avastin; Genentech) for neovascular AMD. Design: Clinical trial. Participants: Eight hundred thirty-four (73%) of 1149 patients participating in the Comparison of AMD Treatments Trials (CATT) were recruited through 43 CATT clinical centers. Methods: Each patient was genotyped for SNPs rs1061170 (CFH), rs10490924 (ARMS2), rs11200638 (HTRA1), and rs2230199 (C3), using TaqMan SNP genotyping assays (Applied Biosystems, Foster City, CA). Main Outcomes Measures: Genotypic frequencies were compared with clinical measures of response to therapy at one year, including mean visual acuity (VA), mean change in VA, 15-letter or more increase in VA, retinal thickness, mean change in total foveal thickness, presence of fluid on OCT, presence of leakage on fluorescein angiography (FA), mean change in lesion size, and mean number of injections administered. Differences in response by genotype were evaluated with tests of linear trend calculated from logistic regression models for categorical outcomes and linear regression models for continuous outcomes. To adjust for multiple comparisons, P≤0.01 was considered statistically significant. Results: No statistically significant differences in response by genotype were identified for any of the clinical measures studied. Specifically, there were no high-risk alleles that predicted final VA or change in VA, the degree of anatomic response (fluid on OCT or FA, retinal thickness, change in total foveal thickness, change in lesion size), or the number of injections. Furthermore, a stepwise analysis failed to show a significant epistatic interaction among the variants analyzed; that is, response did not vary by the number of risk alleles present. The lack of association was similar whether patients were treated with ranibizumab or bevacizumab or whether they received monthly or pro re nata dosing. Conclusions: Although specific alleles for CFH, ARMS2, HTRA1, and C3 may predict the development of AMD, they did not predict response to anti-vascular endothelial growth factor therapy. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

UR - http://www.scopus.com/inward/record.url?scp=84875209738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875209738&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2012.11.037

DO - 10.1016/j.ophtha.2012.11.037

M3 - Article

C2 - 23337555

AN - SCOPUS:84875209738

VL - 120

SP - 593

EP - 599

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 3

ER -